Navigation Links
WaferGen Announces Management Team Promotions

FREMONT, Calif., March 3 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today announced the promotion of two members of the company's management team. Kumar Kastury, Ph.D., director of assay development, has been promoted to vice president of assay development and John McEntee, director of engineering, has been promoted to associate vice president of engineering. The company also announced that Terry W. Osborn, Ph.D., MBA, chief operating officer, is leaving WaferGen to pursue other interests.

"John and Kumar have both made key contributions to WaferGen since joining the company. Considering their previous work and extensive industry expertise, both of these promotions are well-deserved," said Alnoor Shivji, chairman and chief executive officer. "At the same time, we would like to acknowledge the valuable service that Terry has provided WaferGen during his tenure with the company. We wish him the very best in his future pursuits."

As vice president of assay development, Dr. Kastury will serve as a key corporate interface with WaferGen's recently established Malaysian subsidiary. He will be responsible for fostering and managing the subsidiary's collaborative relationships while also overseeing the group's SmartChip(TM) Real-Time PCR System assay development activities, including the development of therapeutically-relevant assays and biomarkers. In his new role as associate vice president of engineering, Mr. McEntee will continue to be responsible for the engineering of the SmartChip Real-Time PCR System, while also coordinating and managing the activities of the company's manufacturing partners in Malaysia.

With extensive experience in the areas of gene expression and cell biology, Dr. Kastury has served as WaferGen's director of research and development since 2007. He joined WaferGen from Gen-Probe Inc. where he was as a senior staff scientist credited with establishing and managing more than ten clinical research collaborations with top oncology thought-leaders. In this role, he also oversaw the successful development of various assays designed to diagnose prostate cancer.

Mr. McEntee has served as WaferGen's director of engineering since 2007. He possesses broad expertise in the development of automated manufacturing equipment, particularly in advancing new technologies from the design stage to market-ready products. Prior to joining WaferGen, Mr. McEnteee held various management positions with Potter Drilling, Xyratex International and Agilent Technologies. At Agilent, he managed a team of engineers responsible for developing the company's microarray manufacturing capability and also led the company's effort to define an optimal automation strategy for the company's microarray technology platform.

About WaferGen

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip(TM) is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform and promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide(TM), which was launched in 2006, represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research. Representative SmartSlide(TM) customers include Harvard University, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, Abbott Labs, and the National Institutes of Health (NIH).

To learn more about WaferGen, please visit the company's web site at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements include statements containing words such as "likely" or "expects" and words of similar import or statements of management's opinion. For such statements, the company claims the protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Quarterly Report on Form 10-Q filed with the SEC on November 13, 2007. Investors and security holders are urged to read this document free of charge on the SEC's web site at The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Vida Communication (On behalf of WaferGen)

Stephanie Diaz (investors) Tim Brons (media)

415-675-7400 415-675-7402

SOURCE WaferGen Biosystems Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
2. WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
4. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
5. DW Healthcare Partners Announces the Sale of Tandem Labs
6. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
7. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
8. Announces Distribution of Spectra Intelligence Research
9. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
10. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
11. Wyeth Announces Executive Change in Finance Organization
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS ... the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US ... absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. ...
(Date:10/11/2017)... CA (PRWEB) , ... October 11, 2017 , ... ... upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding the ... system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at . ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):